ATE525083T1 - Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung - Google Patents
Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindungInfo
- Publication number
- ATE525083T1 ATE525083T1 AT04797450T AT04797450T ATE525083T1 AT E525083 T1 ATE525083 T1 AT E525083T1 AT 04797450 T AT04797450 T AT 04797450T AT 04797450 T AT04797450 T AT 04797450T AT E525083 T1 ATE525083 T1 AT E525083T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical composition
- asp
- insulin
- analog
- active compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301689 | 2003-11-13 | ||
PCT/DK2004/000788 WO2005046716A1 (en) | 2003-11-13 | 2004-11-12 | Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE525083T1 true ATE525083T1 (de) | 2011-10-15 |
Family
ID=34585770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04797450T ATE525083T1 (de) | 2003-11-13 | 2004-11-12 | Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1684793B1 (de) |
JP (1) | JP4800959B2 (de) |
AT (1) | ATE525083T1 (de) |
ES (1) | ES2373660T3 (de) |
WO (1) | WO2005046716A1 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1412384B1 (de) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
EP3572106A1 (de) | 2003-04-23 | 2019-11-27 | Valeritas, Inc. | Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten |
CN102940879B (zh) | 2003-06-03 | 2017-06-06 | 诺沃挪第克公司 | 稳定化的药物肽组合物 |
PL1633391T3 (pl) | 2003-06-03 | 2012-03-30 | Novo Nordisk As | Stabilizowane farmaceutycznie kompozycje peptydowe |
RU2421238C2 (ru) | 2003-11-20 | 2011-06-20 | Ново Нордиск А/С | Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах |
JP4865565B2 (ja) * | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Glp−1アゴニストを用いた食物選択の制御 |
US9089636B2 (en) | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
ES2442223T3 (es) | 2004-08-31 | 2014-02-10 | Novo Nordisk A/S | Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas |
ES2575984T3 (es) * | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal |
PL1817048T3 (pl) * | 2004-11-12 | 2014-07-31 | Novo Nordisk As | Stabilne preparaty peptydów insulinotropowych |
CA2646324C (en) | 2006-03-30 | 2016-06-07 | Valeritas, Llc | Multi-cartridge fluid delivery device |
US20090318353A1 (en) | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
EP2209800B1 (de) | 2007-11-16 | 2013-07-24 | Novo Nordisk A/S | Haltbare pharmazeutische zusammensetzung enthaltend liraglutide und degludec |
WO2009075859A2 (en) * | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
PL2229407T3 (pl) | 2008-01-09 | 2017-06-30 | Sanofi-Aventis Deutschland Gmbh | Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania |
PT3228320T (pt) * | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
JP5973918B2 (ja) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Glp−1アゴニスト及びメチオニンを含む薬学的組成物 |
TR201809460T4 (tr) | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
EP2523655A2 (de) * | 2010-01-12 | 2012-11-21 | Novo Nordisk A/S | Pharmazeutische zusammensetzungen zur oralen verabreichung von insulinpeptiden |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
EP2934569A1 (de) | 2012-12-21 | 2015-10-28 | Sanofi | Exendin-4-derivate |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
EP3080152A1 (de) | 2013-12-13 | 2016-10-19 | Sanofi | Nicht-acylierte exendin-4-peptidanaloga |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
CN105899191B (zh) | 2014-01-09 | 2020-06-16 | 赛诺菲 | 胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂 |
BR112016015851A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
CA2970200A1 (en) | 2014-12-12 | 2016-06-16 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
TW201630622A (zh) * | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | 速效胰島素組合物 |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
CN111050750A (zh) | 2017-08-24 | 2020-04-21 | 诺沃挪第克公司 | Glp-1组合物及其用途 |
EP4106727A1 (de) | 2020-02-18 | 2022-12-28 | Novo Nordisk A/S | Pharmazeutische formulierungen |
AU2021404497A1 (en) * | 2020-12-16 | 2023-06-08 | Zealand Pharma A/S | Pharmaceutical composition of glp-1/glp-2 dual agonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH25772A (en) * | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
PT93057B (pt) * | 1989-02-09 | 1995-12-29 | Lilly Co Eli | Processo para a preparacao de analogos da insulina |
US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
DE122009000079I2 (de) * | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
JP2000517308A (ja) * | 1996-08-30 | 2000-12-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―2誘導体 |
DK0996459T3 (da) * | 1997-01-07 | 2006-01-16 | Amylin Pharmaceuticals Inc | Anvendelse af exendiner og agonister deraf til reduktion af födeindtagelse |
AU5760900A (en) * | 1999-06-25 | 2001-01-31 | Minimed, Inc. | Multiple agent diabetes therapy |
EP1076066A1 (de) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptide zur Senkung des Blutglukosespiegels |
WO2001051071A2 (en) * | 2000-01-11 | 2001-07-19 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
WO2003020201A2 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
-
2004
- 2004-11-12 JP JP2006538658A patent/JP4800959B2/ja not_active Expired - Fee Related
- 2004-11-12 EP EP04797450A patent/EP1684793B1/de not_active Not-in-force
- 2004-11-12 AT AT04797450T patent/ATE525083T1/de not_active IP Right Cessation
- 2004-11-12 WO PCT/DK2004/000788 patent/WO2005046716A1/en active Application Filing
- 2004-11-12 ES ES04797450T patent/ES2373660T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
EP1684793A1 (de) | 2006-08-02 |
JP2007510675A (ja) | 2007-04-26 |
ES2373660T3 (es) | 2012-02-07 |
EP1684793B1 (de) | 2011-09-21 |
JP4800959B2 (ja) | 2011-10-26 |
WO2005046716A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE525083T1 (de) | Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung | |
WO2006051103A3 (en) | Stable formulations of peptides | |
MXPA04003569A (es) | Mezclas bifasicas de glp-1 e insulina. | |
MXPA05007470A (es) | Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2. | |
ATE347901T1 (de) | Exendine zur glucagon suppression | |
WO2005021022A3 (en) | Stable formulations of peptides | |
IL176541A0 (en) | Intranasal administration of glucose-regulating peptides | |
MX2007005521A (es) | Formulaciones estables de peptidos insulinotropicos. | |
CL2010001275A1 (es) | Metodo para producir un producto intermedio compactado de bibw 2992 ma2 que comprende una etapa de compactacion por rodillos de bibw 2992 ma2 u opcionalmente en una premezcla con 0-1,0% de lubricante en un mezclador de caida libre o de volteo y una etapa de tamizado; producto intermedio compactado; comprimido. | |
HK1148689A1 (en) | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates | |
WO2006097535A3 (en) | Peptide agonists of the glucagon family with secretin like activity | |
AU2003266133A1 (en) | Materials and methods for drug delivery and uptake | |
AU2003295614A8 (en) | Delivery of pharmaceutical agents via the human insulin receptor | |
YU98503A (sh) | Pulmonarno ordiniranje hemijski modifikovanog insulina | |
CL2009001899A1 (es) | Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01). | |
SG160437A1 (en) | Modified human growth hormone | |
PL1609481T3 (pl) | Nadająca się do wstrzykiwania kompozycja farmaceutyczna zawierająca diklofenak sodowy, beta-cyklodekstrynę i polisorbat | |
CY1113755T1 (el) | Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2 | |
WO2004050115A3 (en) | Combination treatment using exendin-4 and thiazolidinediones | |
ATE354362T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
ZA200208761B (en) | Pharmaceutical form of administration for peptides, methods for its production and use. | |
WO2005082004A3 (en) | Rationally designed antibodies having a domain-exchanged scaffold | |
MXPA05010613A (es) | Formulacion parenteral de acido micofenolico, una sal o profarmaco del mismo. | |
UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
MXPA03001227A (es) | Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |